Former Insys Sales Rep Pleads Guilty to Violating Kickback Laws
- Last Updated: July 27th, 2023
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Former Insys Sales Rep Pleads Guilty to Violating Kickback Laws
Insys Therapeutics and its marketing of the cancer drug Subsys continues to create drama in the court system, as a former sales rep has pleaded guilty to violating federal kickback laws in connection with an alleged scheme to boost sales of the opioid painkiller.
According to court documents filed in the case, two physicians in Mobile, Alabama operated a pain management clinic.
Between 2012 (when Subsys entered the market) and 2013, they become the top prescribers of the medication in the nation, together writing 100 prescriptions for Subsys; however, of the thousands of patients the doctors treated, very few actually had cancer.
Insys allegedly compensated the physicians for prescribing the drug by paying them nearly $210,000 in speaking and consulting fees, payments that the feds say were actually kickbacks and violated federal law.
The doctors were arrested last summer and face trial in July 2016 for allegations of fraud and conspiracy.
Table of Contents
What is Subsys?
Subsys, approved in 2011 to treat acute cancer pain, is a spray form of the fentanyl narcotic with only one FDA-approved use: the management of breakthrough pain in adult cancer patients who are already receiving and who are tolerant to around-the clock opioid therapy for their underlying persistent cancer pain.
Claims that the company encouraged doctors to prescribe Subsys for unapproved uses are currently being investigated by various federal and state agencies.
The medication carries a high risk of dependency, and recent data released by the U.S. Centers for Disease Prevention and Control (CDC) found that the rate of opioid overdose deaths rose 14 percent from 2013 to 2014.
An earlier report found that 74 percent of the nearly 23,000 US deaths from painkillers in 2011 were due to overdose.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
